Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jul-Aug;20(4):418-28.
doi: 10.4103/2230-8210.183460.

Triglyceride and cardiovascular risk: A critical appraisal

Affiliations

Triglyceride and cardiovascular risk: A critical appraisal

Awadhesh Kumar Singh et al. Indian J Endocrinol Metab. 2016 Jul-Aug.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Major statin and fibrates trials in order of their publication
Figure 2
Figure 2
Residual cardiovascular risk in major statin trials (statin vs. control)
Figure 3
Figure 3
Residual risk still persisting with statins in major statin trials
Figure 4
Figure 4
Risk reduction with conventional versus intensive statin therapy
Figure 5
Figure 5
Residual cardiovascular risk after intensive statin therapy
Figure 6
Figure 6
Outcomes with statins in diabetes versus no diabetes
Figure 7
Figure 7
Residual risk with statins in diabetes versus no diabetes
Figure 8
Figure 8
Cardiovascular risk reduction in different subgroups across fibrate trials
Figure 9
Figure 9
Difference in triglycerides and high-density lipoprotein with different fibrates

Similar articles

Cited by

References

    1. Jacobs DR, Jr, Barrett-Connor E. Retest reliability of plasma cholesterol and triglyceride. The Lipid Research Clinics Prevalence Study. Am J Epidemiol. 1982;116:878–85. - PubMed
    1. Criqui MH, Heiss G, Cohn R, Cowan LD, Suchindran CM, Bangdiwala S, et al. Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med. 1993;328:1220–5. - PubMed
    1. West KM, Ahuja MM, Bennett PH, Czyzyk A, De Acosta OM, Fuller JH, et al. The role of circulating glucose and triglyceride concentrations and their interactions with other “risk factors” as determinants of arterial disease in nine diabetic population samples from the WHO multinational study. Diabetes Care. 1983;6:361–9. - PubMed
    1. Recommendations on Lipoprotein Measurement. Bethesda, MD: National Institutes of Health, National Heart, Lung, and Blood Institute, NIH publication No. 95-3044; 1995. National Cholesterol Education Program (U.S.). Working Group on Lipoprotein Measurement.
    1. Zilversmit DB. Atherogenesis: A postprandial phenomenon. Circulation. 1979;60:473–85. - PubMed